Reuters logo
BRIEF-Ionis enters into collaboration with Ribo to advance RNA-targeted therapeutics in China
2017年4月18日 / 上午11点19分 / 5 个月前

BRIEF-Ionis enters into collaboration with Ribo to advance RNA-targeted therapeutics in China

April 18 (Reuters) - Ionis Pharmaceuticals Inc

* Ionis enters into collaboration with ribo to advance rna-targeted therapeutics in china

* Ionis pharmaceuticals inc - granted ribo license for right to commercialize in china two ionis generation 2+ antisense drugs in metabolic disease, cancer

* Ionis will receive an undisclosed up-front payment and equity in ribo

* Ionis pharma - ribo will be responsible for conducting multi-year research & drug discovery program to identify drugs that utilize ionis’ ssrnai technology

* Ionis pharmaceuticals inc - ionis retains rights to develop and commercialize ssrnai technology and all drugs under collaboration outside of china

* Ribo will provide ionis a royalty-free license to data and intellectual property created under collaboration Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below